Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YTS109 Cell for Relapsed/Refractory Autoimmune Hemolytic Anemia
NCT07453836Phase 1Not yet recruiting
- Sponsor
- China Immunotech
- Start
- Nov 2026
- Primary completion
- Mar 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of YTS-109 in autoimmune hemolytic anemia (AIHA), sponsored by China Immunotech. Primary endpoints: Dose Limiting Toxicity at 28 days and Treatment-Emergent Adverse Events at 6 months. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
YTS-109
03
Conditions
autoimmune hemolytic anemia (AIHA)
Beyond the preview
Go deeper on NCT07453836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07453836.